Novartis received a cut from Hold to Sell, a negative sign for its stock. The report gives no new information about its medicines or sales, so it signals weaker confidence rather than a newly reported business setback.
The change makes the bank's view of Novartis's stock more negative. The report gives no reason for the cut and names no new problem with Novartis's medicines or business. This points to weaker confidence, not a newly reported business setback.
Follow Novartis AG (NVS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NVS